247 results
Page 7 of 13
424B5
sg1 dd8gjeq6nwxh
6 May 22
Prospectus supplement for primary offering
7:15am
8-K
EX-10.1
9d41i2v
6 May 22
Entry into a Material Definitive Agreement
6:02am
8-K
EX-99.1
f1s0j9sm 3u
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.2
7h3qksrydxyi q6x84
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.3
i6jkpj4e3dae4es4
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.1
l4y theev
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.2
34vjexuwh5e yvpj51c
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
8p05y40
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.2
etxqdn
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
8-K
EX-99.1
88iaf
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
424B5
l66njnac6z
9 Feb 22
Prospectus supplement for primary offering
4:08pm
8-K
3x55f58 6a8gx3z
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
p688el1dh
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
eg98jri
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
EX-99.1
mrvbivn6eledsxwc9
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am